Validated Prognostic and Predictive Biomarkers in Breast Cancer

Monogram Biosciences, HERmarkTM Breast Cancer Assay: Prior to acquisition by LabCorp, developed educational slide libraries, white papers, advisory boards, and symposia at ASCO and SABCS

Breast cancer-Roche/Herceptin®; GSK/Tykerb®

Breast cancer diagnostics – Genoptix Medical Laboratory; Monogram Biosciences

Genoptix Medical Laboratory-Novartis/Breast Cancer: Data published by the American Society for Clinical Oncology (ASCO) and the College of American Pathologists (CAP) has demonstrated that 1 in 5 of the results generated by tests commonly used to determine treatment for breast cancer are inaccurate. Community oncologists, who treat 80% of women with breast cancer, lack awareness of this critical issue.

Medical Minds identified and recruited a panel of KOLs from major institutions in the US and UK and worked with them to create a foundational slide library. The slide library will be used in a nationwide educational initiative to educate community oncologists on the appropriate use of breast cancer predictive and prognostic biomarkers in clinical practice.

 

 

Breast Cancer Educational Initiative Advisory Panel 

Oncologists

Cliff Hudis, MD – Memorial Sloan Kettering

Alan Lipton, MD – Penn State University

Joyce Ann O’Shaughnessy, MD – Texas Oncology

Edith Perez, MD – Mayo Clinic

Hope Rugo, MD – UCSF

Antonio Wolff, MD – Johns Hopkins

Pathologists

Mitch Dowsett, PhD – Royal Marsden, London, UK

David Rimm, MD – Yale University School of Medicine

Baljit Singh, MD, PhD – New York University Medical Center